STOCK TITAN

Impact Biomedical shareholders approve merger agreement

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Impact Biomedical Inc. (IBO) stockholders approved and adopted the Merger and Share Exchange Agreement, as amended. The proposal received 7,713,011 votes for, 2,002 against and 197 abstentions. At the special meeting on November 13, 2026, 7,715,210 shares were represented, equal to 89.29% of the 8,640,000 shares eligible to vote as of October 13, 2026, and constituting a quorum.

Stockholders also approved the Amended and Restated Memorandum and Articles of Association; elected Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady and Chan Heng Fai Ambrose to serve as directors until the next annual meeting; and ratified Grassi & Co. Certified Public Accountants, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. They approved named executive officer compensation on an advisory basis and approved adjournment if necessary. The company said adjournment was unnecessary because sufficient votes had been received.

Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Merger agreement vote 7,713,011 for; 2,002 against; 197 abstentions Stockholder vote at the November 13, 2026 special meeting
Shares represented 7,715,210 shares At the November 13, 2026 special meeting; constituted a quorum
Shares eligible to vote 8,640,000 shares As of October 13, 2026, the record date
Represented shares 89.29% Share of the 8,640,000 shares eligible to vote as of October 13, 2026
Amended articles vote 7,600,533 for; 114,489 against; 188 abstentions Approval of the Amended and Restated Memorandum and Articles of Association
Auditor ratification vote 7,712,827 for; 1,300 against; 1,083 abstentions Appointment for the fiscal year ending December 31, 2026
Executive compensation vote 7,506,873 for; 208,159 against; 178 abstentions Advisory approval of named executive officer compensation
Merger and Share Exchange Agreement technical
"approved and adopted the Merger and Share Exchange Agreement, as amended"
Amended and Restated Memorandum and Articles of Association technical
"Approval of the Amended and Restated Memorandum and Articles of Association"
A document that replaces and combines a company’s core governing papers into a single, updated set of rules spelling out the company’s purpose, share structure, voting rights and how decisions are made. Think of it as rewriting and consolidating a household’s rulebook so everyone knows who controls what and how major choices are handled. Investors watch these changes because they can alter ownership rights, governance, dividend policy and takeover protections, affecting value and control.
quorum technical
"constituting a quorum"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
advisory basis technical
"approved, on an advisory basis, the compensation"
broker non-votes technical
"BROKER NON-VOTES"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did IBO shareholders approve the merger agreement?

Yes. Stockholders approved and adopted the Merger and Share Exchange Agreement, as amended, with 7,713,011 votes for, 2,002 against and 197 abstentions.

How many IBO shares were represented at the special meeting?

A total of 7,715,210 shares were represented, equal to 89.29% of the 8,640,000 shares eligible to vote as of October 13, 2026. The represented shares constituted a quorum.

Who was elected to IBO's board of directors?

Stockholders elected Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel Hibbert, David Keene, Christian Zimmerman, Jason Grady and Chan Heng Fai Ambrose to serve as directors until the next annual meeting.

What other proposals did IBO shareholders approve?

Stockholders approved the Amended and Restated Memorandum and Articles of Association, ratified Grassi & Co. Certified Public Accountants, P.C. for the fiscal year ending December 31, 2026, and approved named executive officer compensation on an advisory basis. They also approved adjournment if necessary, but the company said adjournment was unnecessary because sufficient votes had been received.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001834105 0001834105 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2026

 

IMPACT BIOMEDICAL INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-42212   85-3926944

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1400 Broadfield Blvd., Suite 130,

Houston, TX

  77084
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (585) 325-3610

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Ticker symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   IBO   The NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On November 13, 2026, Impact Biomedical Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). A total of 7,715,210 shares of common stock of the Company, representing 89.29% of the 8,640,000 aggregate shares outstanding and eligible to vote on October 13, 2026, the record date for the Special Meeting, and constituting a quorum, were represented in person or by valid proxies at the Special Meeting.

 

The stockholders approved and adopted the Merger and Share Exchange Agreement, dated June 21, 2025, as amended, by and among Zoar Limited (f.k.a Dr Ashleys Limited), a Cayman Islands exempted company limited by shares (“PubCo”), Impact, Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly-owned subsidiary of PubCo (“Merger Sub”), Zoar Labs Limited (f.k.a Dr Ashleys Bio Labs Limited), a Cayman Islands exempted company limited by shares (“Zoar”), and Kanans Visvanats (a.k.a Kannan Vishwanatth), a Latvian national, solely in his capacity as the sole stockholder (“Zoar Shareholder”) of Zoar (the “Original Merger and Share Exchange Agreement”). The Original Merger and Share Exchange Agreement was amended by an amendment dated February 27, 2026, which was rescinded and superseded by an amendment dated June 30, 2026 (the “Amended and Restated Amendment to the Original Merger and Share Exchange Agreement”), and was further amended by an amendment dated August 13, 2026 (the “Second Amended and Restated Amendment to the Original Merger and Share Exchange Agreement,” and together with the Original Merger and Share Exchange Agreement, the Amended and Restated Amendment to the Original Merger and Share Exchange Agreement, and as it may be subsequently amended from time to time, the “Merger and Share Exchange Agreement”);

 

The stockholders also approved the election of Frank D. Heuszel; Elise Brownell; Melissa Sims; Castel Hibbert; David Keene; Christian Zimmerman; Jason Grady and Chan Heng Fai Ambrose to serve as directors of the Company until the next Annual Meeting of the shareholders.

 

The stockholders ratified the appointment of Grassi & Co. Certified Public Accountants, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

 

Additionally, the stockholders approved, on an advisory basis, the compensation of the named executive officers. The stockholders also approved the adjournment of the Special Meeting, if necessary; however, because there were sufficient votes to approve the foregoing proposals, adjournment of the Special Meeting was not necessary.

 

The final voting results on these matters were as follows:

 

1. Approval and adoption of the Merger Agreement:

 

FOR   AGAINST ABSTAIN
7,713,011   2,002   197

 

2. Approval of the Amended and Restated Memorandum and Articles of Association:

 

FOR   AGAINST ABSTAIN
7,600,533   114,489   188

 

3. Approval of the election of Frank D. Heuszel; Elise Brownell; Melissa Sims; Castel Hibbert; David Keene; Christian Zimmerman; Jason Grady and Chan Heng Fai Ambrose to serve as directors of the Company until the next Annual Meeting of the shareholders:

 

   FOR   AGAINST   ABSTAIN   BROKER NON-VOTES 
Frank D. Heuszel   7,711,539    2,326    1,345    — 
Elise Brownell   7,637,341    2,272    75,597    — 
Melissa Sims   7,600,121    2,631    112,458    — 
Castel Hibbert   7,711,056    2,291    1,863    — 
David Keene   7,711,082    2,285    1,843    — 
Christian Zimmerman   7,710,909    2,960    1,341    — 
Jason Grady   7,672,314    2,245    40,651    — 
Chan Heng Fai Ambrose   7,579,387    2,873    132,950    — 

 

4. Ratification of the appointment of Grassi & Co. Certified Public Accountants, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:

 

FOR   AGAINST   ABSTAIN
7,712,827   1,300   1,083

 

5. Approval on an advisory basis of the compensation of the named executive officers:

 

FOR   AGAINST ABSTAIN   BROKER NON-VOTES
7,506,873   208,159   178   —

 

6. Approval of the adjournment of the Special Meeting, if necessary:

 

FOR   AGAINST ABSTAIN   BROKER NON-VOTES
7,671,841   42,856   513   —

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMPACT BIOMEDICAL INC.
     
Date: November 17, 2026 By: /s/ Frank D. Heuszel
  Name: Frank D. Heuszel
  Title: Chief Executive Officer

 

 

Filing Exhibits & Attachments

3 documents

Keep reading